These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11245323)

  • 1. HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination.
    Macías J; Pineda JA; Leal M; Abad MA; Delgado J; Rosa R; Rubio A; Sánchez-Quijano A; Lissen E
    Eur J Clin Microbiol Infect Dis; 2001 Jan; 20(1):46-8. PubMed ID: 11245323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.
    Günthard HF; Wong JK; Spina CA; Ignacio C; Kwok S; Christopherson C; Hwang J; Haubrich R; Havlir D; Richman DD
    J Infect Dis; 2000 Feb; 181(2):522-31. PubMed ID: 10669335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.
    Di Mascio M; Ribeiro RM; Markowitz M; Ho DD; Perelson AS
    Math Biosci; 2004; 188():47-62. PubMed ID: 14766093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study.
    Boillat-Blanco N; Darling KE; Schoni-Affolter F; Vuichard D; Rougemont M; Fulchini R; Bernasconi E; Aouri M; Clerc O; Furrer H; Günthard HF; Cavassini M;
    Antivir Ther; 2015; 20(2):165-75. PubMed ID: 24964403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.
    Easterbrook PJ; Ives N; Waters A; Mullen J; O'Shea S; Peters B; Gazzard BG
    AIDS; 2002 Jul; 16(11):1521-7. PubMed ID: 12131190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful simplification of HAART in patients with acute primary HIV infection.
    Sinicco A; Bonora S; Arnaudo I; Zeme DA; Audagnotto S; Raiteri R; Di Perri G
    J Biol Regul Homeost Agents; 2002; 16(1):69-72. PubMed ID: 12003178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
    Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance.
    Kaplan SS; Ferrari G; Wrin T; Hellmann NS; Tomaras GD; Gryszowka VE; Fiscus SA; Weinhold KJ; Hicks CB
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):13-6. PubMed ID: 15665640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
    J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads.
    Kolber MA; Gabr AH; De La Rosa A; Glock JA; Jayaweera D; Miller N; Dickinson GM
    AIDS; 2002 Mar; 16(4):537-42. PubMed ID: 11872996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
    Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
    JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.
    Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Palmisano L; Andreotti M; Andreoni C; Giuliano M; Gatti F; Boldrin C; Palù G; Vullo V; Vella S; Andreoni M
    J Clin Microbiol; 2005 Dec; 43(12):6183-5. PubMed ID: 16333125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy.
    Montoya CJ; Toro MF; Aguirre C; Bustamante A; Hernandez M; Arango LP; Echeverry M; Arango AE; Prada MC; Alarcon Hdel P; Rojas M
    Mem Inst Oswaldo Cruz; 2007 Jun; 102(4):501-8. PubMed ID: 17612772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.
    Tanzi E; Esposito S; Bojanin J; Amendola A; Trabattoni D; Pariani E; Pinzani R; Zanetti A; Principi N
    J Med Virol; 2006 Apr; 78(4):440-5. PubMed ID: 16482542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 DNA and RNA kinetics in primary HIV infection.
    Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
    Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
    AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy.
    Macias J; Palomares JC; Mira JA; Torres MJ; García-García JA; Rodríquez JM; Vergera S; Pineda JA
    J Infect; 2005 Oct; 51(3):195-200. PubMed ID: 16230215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.